Insights

Strategic focus POZEN operates with a unique in-source model and has a proven track record of FDA approvals for self-invented products, indicating a capability to rapidly bring integrated therapies to market and pursue co-development or licensing collaborations.

Affordable therapies The company emphasizes developing affordable medicines to address unmet needs, creating sales opportunities in price-sensitive markets and with payers seeking cost-effective treatment options.

Niche portfolio POZEN specializes in combining existing drug therapies to create novel pharmacologic agents, suggesting potential for partnership in combination therapies or licensing deals that enhance existing product lines.

Small but agile With a lean headcount (11-50) and revenue in the lower tens of millions, POZEN may be open to expedited deals, milestone-rich collaborations, and flexible commercialization arrangements.

Pipeline and partnerships Historical emphasis on licensing products to other companies for commercialization presents opportunities for BD activities around in-licensing, co-development, or strategic alliances leveraging their FDA-validated self-invented approaches.

Similar companies to POZEN

Sanofi
93K$10B+
Johnson & Johnson
134K$10B+
Pfizer
109K$10B+
AstraZeneca
82K$10B+
AbbVie
60K$10B+
Ironwood Pharmaceuticals
259$250M - $500M
Novartis
87K$10B+
Bayer
96K$10B+
Eli Lilly and Company
58K$10B+

Media & News

POZEN Inc. to Announce Third Quarter 2015 Results on November 9, 2015
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN) today announced that the Company plans to release results for the third quarter 2015 on Monday, November 9, 2015, before the opening of the U.S. markets. The Company also will conduct a conference call that day at 11:00 a.m. ET to discuss results and highlights of the third quarter of 2015. The presentation slides to be used during the call will be available on the "Investors" section of the Company's website under the "Overview" tab beginning at 11:00 a.m. ET on Monday, November 9, 2015. A live webcast of the conference call, presentation and question and answer session will be available on the "Investors" section of the Company's website under the "Overview" tab. To access the live webcast, please log on to POZEN's site approximately 15 minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for 90 days after the event. Conference call details:Date: Monday, November 9, 2015Time: 11:00 a.m. ETDial-in (U.S.): 877-407-8037Dial-in (International): 201-689-8037Webcast: www.pozen.com About POZEN POZEN Inc. is a specialty pharmaceutical company that to date has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. POZEN’s common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
Oct 26, 2015 | www.businesswire.com

POZEN's Email Address Formats

POZEN uses at least 4 email formats:

POZEN Email Formats	Example	Percentage
FLast@pozen.com	JDoe@pozen.com	79%
First.Last@pozen.com	John.Doe@pozen.com	10%
First@pozen.com	John@pozen.com	7%
F.Last@pozen.com	J.Doe@pozen.com	4%

Frequently Asked Questions

What is POZEN's phone number?

You can contact POZEN's main corporate office by phone at

+1-919-913-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is POZEN's stock symbol?

POZEN is a publicly traded company; the company's stock symbol is POZN.

What is POZEN's official website and social media links?

POZEN's official website is pozen.com and has social profiles on LinkedIn.

How much revenue does POZEN generate?

As of November 2026, POZEN's annual revenue is estimated to be $10M - $25M.

What is POZEN's SIC code and NAICS code?

POZEN's SIC code is 2834 - Pharmaceutical Preparations and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does POZEN have currently?

As of November 2026, POZEN has approximately 28 employees across 3 continents, including North America, Asia and Europe. Key team members include Senior Director , Marketing: W. S., Clinical Research Associate Ii: C. M. and General Medical Practice: D. L. Explore POZEN's employee directory with LeadIQ.

What industry does POZEN belong to?

POZEN operates in the Pharmaceutical Manufacturing industry.

What is POZEN's email format?

POZEN's email format typically follows the pattern of FLast@pozen.com. Find more POZEN email formats with LeadIQ.

When was POZEN founded?

POZEN was founded in 1996.

POZEN

Q: What is POZEN's official website and social media links?

POZEN's official website is pozen.com. POZEN has social profiles on LinkedIn.

Q: How many employees does POZEN have currently?

POZEN has approximately 28 employees.

Q: What is POZEN's NAICS code?

POZEN's NAICS code is 3254 (Pharmaceutical and Medicine Manufacturing).

Pharmaceutical ManufacturingNorth Carolina, United States11-50 Employees

POZEN Inc. is a small to mid-sized pharmaceutical company based in Chapel Hill, North Carolina, founded in 1996. It pursues an in-source, specialty-model approach to developing integrated therapies by combining existing drug therapies into novel pharmacologic agents. This strategy aims to address unmet medical needs and offer affordable medicines for patients and physicians, with an emphasis on increasing the likelihood of clinical success versus traditional new chemical entity programs.

The company has obtained FDA approval for two self-invented products. Its portfolio centers on aspirin-based integrated therapies intended to reduce aspirin-related GI damage while preserving therapeutic benefit. In addition to development, POZEN licenses its products to other pharmaceutical firms for commercialization, aligning its activities with a broader market reach.